Abstract
Induction therapy refers to the blocking of molecules involved in transplant immunity by an antibody or a soluble receptor during the peritransplant period. The critical biological event that characterizes the immediate post-transplant period is the increased expression of adhesion and co-stimulatory molecules, such as selectins, ICAMs, VCAMs and B7, throughout the graft as a consequence of the ischemia/reperfusion injury [1]. This may have two deleterious consequences. First, adhesion molecules are able to recruit and activate polymorphonuclear cells, a process which contributes to the development of delayed graft function. Second, the inflamed allograft may also promote the early migration and activation of alloreactive T cells, which may trigger acute rejection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fuggle SV, Koo DD. Cell adhesion molecules in clinical renal transplantation. Transplantation. 1998; 65: 763–769.
Michael J, Francos GC, Burke JF et al. A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients. Transplantation. 1989; 46: 805–808.
Belitsky AS, MacDonald AS, Cohen AD et al. Comparison of antilymphocyte globulin and continuous i.v. cyclosporin as induction immunosuppression for cadaver kidney transplants: a prospective randomized study. Transplant. Proc. 1991; 23: 999–1000.
Banhegyi C, Rockenschaub S, Muhlbacher F et al. Preliminary results of a prospective randomized clinical trial comparing cyclosporin A to antithymocyte globulin immunosuppressive induction therapy in kidney transplantation. Transplant. Proc. 1991; 23: 2207–2208.
Abramowicz D, Goldman M, De Pauw L, Vanherweghem J.L, Kinnaert P, Vereerstraeten P. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation: A single-center, prospective, randomized study. Transplantation. 1992; 54: 433–437.
Norman DJ, Kahana L, Stuart FP et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation. 1993; 55: 44–50.
Slakey DP, Johnson CP, Callaluce RD et al. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function. Transplantation. 1993; 56: 827–831.
Spanish Monotherapy Study Group. Cyclosporine monotherapy versus OKT3 and cyclosporine as induction therapy in older renal transplant patients: A multicenter randomized study. Transplant. Proc. 1994; 26: 2522–2524.
Thibaudin D, Alamartine E, de Filippis JP, Diab N, Blandine L, Berthoux F. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol. Dial. Transplant. 1998; 13: 711–715.
Szczech LA, Berlin JA, Aradhye S, Grossmann RA, Feldman HI. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J. Am. Soc. Nephrol. 1997; 8: 1771–1777.
Shield CF, Edwards EB, Davies DB, Daily OP. Antilymphocyte induction therapy in cadaver renal transplantation. Transplantation. 1997; 63: 1257–1263.
Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation. 1995; 60: 1220–1224.
Opelz G. Efficacy of rejection prophylaxis with OKT3 (letter). Transplantation. 1996; 62: 70.
Cecka JM, Gjertson D, Terasaki PI. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups? Transplant. Proc. 1993; 25: 548–549.
Abramowicz D, Norman DJ, Vereerstraeten P et al. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int. 1996; 49: 768–772.
Gaber AO, First MR, Testi RJ, Gaston RS, Mendez R. Results of the double-blind randomized, multicenter, phase III clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998; 66: 29–37.
Lebranchu Y et al. A randomized, double-blind, multicenter trial comparing two corticosteroid regimens in combination with mycophenolate mofetil (MMF) and cyclosporine (CYA) in renal transplant recipients. Transplantation Society XVII congress 1998; abstract book p. 14.
Henry ML, Elkhammas EA, Bumgardner GL, Davies EA, Pelletier RP, Ferguson RM. Antibody induction in the current era. Transplantation. 1998; 65: S65.
Charpentier B et al. A randomized multicenter trial of Tacrolimus in renal transplantation comparing induction vs. non-induction therapy. Transplantation Society XVII congress 1998; Abstract book p. 115.
Pescovitz MD et al. Safety of the new antibodies. Transplantation Society XVII congress 1998; Abstract book p. 90.
Nashan B, More R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 1997; 350: 1193–1198.
Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N. Engl J Med. 1998; 338: 161–165.
Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Transplantation. 1999; 67: 110–115.
Kovarik JM, Gerbeau C, Hall M, Schmidt AG. Influence of the duration of IL-2 receptor (IL-2R) blockade on the incidence of acute rejection episodes in renal transplantation. Transplantation. 1998; 65: S179.
Kelly KJ, Williams WW, Colvin RB, Bonventre JV. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc. Natl. Acad. Sci. USA. 1994; 91: 812–816.
Hourmant M, Bedrossian J, Durand D et al. A randomized multicenter trial comparing leucocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation. 1996; 62: 1565–1570.
Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N. Engl J Med. 1998; 1813–1821.
Alegre ML. Costimulatory molecules as targets for the induction of transplantation tolerance. Nephrol. Dial. Transplant. 1999; 14: 322–332.
Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science. 1992; 255: 1125–1127.
Kirk AD, Harlan DM, Amstrong NN. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA. 1997; 94: 8789–8794.
Editor information
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Abramowicz, D., Wissing, K.M. (1999). Induction therapy. In: Cochat, P., Traeger, J., Merieux, C., Derchavane, M. (eds) Immunosuppression under Trial. Transplantation and Clinical Immunology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4643-2_15
Download citation
DOI: https://doi.org/10.1007/978-94-011-4643-2_15
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5960-2
Online ISBN: 978-94-011-4643-2
eBook Packages: Springer Book Archive